Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19195101 | SYSTEMS AND METHODS OF DIAGNOSING IDIOPATHIC PULMONARY FIBROSIS | April 2025 | February 2026 | Abandon | 9 | 1 | 0 | No | No |
| 19026709 | TARGET RECOGNITION METHODS BASED ON ELECTROENCEPHALOGRAM SIGNALS IN NATURAL READING ENVIRONMENT | January 2025 | December 2025 | Abandon | 11 | 2 | 0 | No | No |
| 18790796 | METHOD FOR CHARACTERIZING INTER-WELL CONNECTIVITY, DEVICE, MEDIUM AND PRODUCT | July 2024 | January 2026 | Abandon | 17 | 2 | 1 | No | No |
| 18710917 | DISEASE OR HEALTH CONDITION EXAMINATION METHOD AND EXAMINATION SYSTEM | May 2024 | January 2026 | Abandon | 20 | 3 | 1 | Yes | No |
| 18591539 | SYSTEMS AND METHODS FOR TREATING, DIAGNOSING AND PREDICTING THE OCCURRENCE OF A MEDICAL CONDITION | February 2024 | November 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18544115 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | December 2023 | March 2025 | Abandon | 15 | 1 | 1 | No | No |
| 18469522 | A METHOD AND SYSTEM FOR INSULIN MANAGEMENT | September 2023 | January 2025 | Allow | 16 | 2 | 0 | Yes | Yes |
| 18357726 | METHOD AND SYSTEM OF CANCER DETECTION USING CPG-SNP CONTAMINATION MARKERS | July 2023 | March 2026 | Allow | 32 | 2 | 1 | Yes | Yes |
| 18324140 | A METHOD AND DOSING CONTROLLER FOR ADMINSTERING A CORRECTION DOSE OF INSULIN | May 2023 | January 2026 | Allow | 32 | 4 | 1 | No | No |
| 18311775 | METHODS AND SYSTEMS FOR LARGE SCALE SCAFFOLDING OF GENOME ASSEMBLIES | May 2023 | November 2025 | Abandon | 30 | 1 | 1 | No | No |
| 18136098 | METHODS AND SYSTEMS FOR DETERMINING A PREGNANCY-RELATED STATE OF A SUBJECT | April 2023 | May 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18301891 | SYSTEMS AND METHODS FOR ASSESSING AND IMPROVING THE QUALITY OF MULTIPLEX MOLECULAR ASSAYS | April 2023 | January 2026 | Abandon | 33 | 5 | 1 | No | No |
| 18189075 | CLASSIFICATION OF NUCLEIC ACID TEMPLATES | March 2023 | March 2024 | Abandon | 12 | 1 | 1 | Yes | No |
| 18165264 | DIRECT CLASSIFICATION OF RAW BIOMOLECULE MEASUREMENT DATA | February 2023 | October 2025 | Abandon | 32 | 3 | 3 | Yes | No |
| 17818944 | METHOD FOR COMPARING DNA MOLECULES | August 2022 | August 2023 | Abandon | 12 | 4 | 2 | No | No |
| 17817581 | METHODS AND SYSTEMS FOR GENOMIC ANALYSIS | August 2022 | December 2024 | Abandon | 28 | 5 | 0 | Yes | No |
| 17813440 | A METHOD AND SYSTEM FOR INSULIN BOLUS MANAGEMENT | July 2022 | June 2023 | Allow | 10 | 2 | 0 | No | No |
| 17703321 | CLASSIFIERS FOR DETECTION OF ENDOMETRIOSIS | March 2022 | July 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17592311 | METHODS AND SYSTEMS FOR DETERMINING A PREGNANCY-RELATED STATE OF A SUBJECT | February 2022 | January 2023 | Abandon | 11 | 1 | 0 | No | No |
| 17624181 | GENOMIC AND EPIGENOMIC COMPARATIVE, INTEGRATIVE PATHWAY DISCOVERY | December 2021 | February 2026 | Abandon | 49 | 1 | 0 | No | No |
| 17560101 | METHOD OF NUCLEAR DNA AND MITOCHONDRIAL DNA ANALYSIS | December 2021 | June 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17542664 | A METHOD AND SYSTEM FOR IDENTIFYING POTENTIAL CONTAMINANTS IN TEST PLATES | December 2021 | July 2023 | Allow | 19 | 4 | 1 | Yes | No |
| 17608105 | INFORMATION PROVISION DEVICE AND METHOD FOR GENERATING MIRNA IMPORTANCE TABLE | November 2021 | March 2024 | Abandon | 29 | 2 | 2 | Yes | No |
| 17604363 | PET FOOD RECOMMENDING DEVICE AND PET FOOD RECOMMENDING METHOD, SUPPLEMENT RECOMMENDING DEVICE AND SUPPLEMENT RECOMMENDING METHOD, AND INTESTINAL AGE CALCULATION FORMULA DETERMINING METHOD AND INTESTINAL AGE CALCULATION METHOD | October 2021 | November 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17474001 | SYSTEM AND METHOD FOR OPTIMIZING INSULIN DOSAGES FOR DIABETIC SUBJECTS | September 2021 | March 2023 | Allow | 18 | 2 | 1 | No | Yes |
| 17404211 | METHODS AND APPARATUSES FOR USING ARTIFICIAL INTELLIGENCE TRAINED TO GENERATE CANDIDATE DRUG COMPOUNDS BASED ON DIALECTS | August 2021 | March 2025 | Abandon | 43 | 4 | 1 | No | Yes |
| 17396490 | SYSTEM FOR DETERMINING A HEALTH STATUS OF A TISSUE OF INTEREST | August 2021 | March 2023 | Abandon | 20 | 3 | 0 | Yes | No |
| 17396457 | SYSTEM FOR DETERMINING A HEALTH STATUS OF A TISSUE OF INTEREST | August 2021 | December 2022 | Abandon | 16 | 2 | 1 | No | No |
| 17429313 | METHOD AND APPARATUS FOR PREDICTING FLUID FLOW THROUGH A SUBJECT CONDUIT | August 2021 | November 2025 | Abandon | 52 | 0 | 1 | No | No |
| 17305658 | A METHOD AND DOSING CONTROLLER FOR SUBCUTANEOUS OUTPATIENT MANAGEMENT | July 2021 | February 2023 | Allow | 19 | 3 | 0 | No | No |
| 17356868 | SYSTEMS AND METHODS OF ASSESSING SIGNIFICANCE OF METABOLITES IN DISEASES | June 2021 | May 2024 | Abandon | 34 | 6 | 0 | No | No |
| 17339368 | METHOD FOR DETERMINING EFFICACY OF CHEMOTHERAPY TREATMENT FOR A SUBJECT | June 2021 | January 2026 | Allow | 56 | 2 | 0 | No | No |
| 17286310 | SYSTEMS AND METHODS OF MANAGING DATA FOR GENOMIC SEQUENCING | April 2021 | November 2024 | Abandon | 43 | 6 | 0 | Yes | No |
| 17281716 | METHODS AND MATERIALS FOR DETECTING GENE COPY NUMBER VARIANTS | March 2021 | March 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17200447 | METHOD FOR PERSONALIZED SELECTION OF A DRUG FOR A SUBJECT | March 2021 | February 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17194823 | Biotechnology for curing hypothyroidism | March 2021 | October 2024 | Abandon | 44 | 2 | 1 | Yes | Yes |
| 17188546 | Method for Assessing Classification Annotations Assigned to DNA Sequences of Organisms | March 2021 | January 2023 | Abandon | 23 | 3 | 1 | Yes | No |
| 17160191 | METHODS AND SYSTEMS FOR GENERATING A VIRTUAL PROGENY GENOME | January 2021 | February 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17089234 | CLASSIFICATION OF TUMOR MICROENVIRONMENTS | November 2020 | January 2026 | Abandon | 60 | 5 | 1 | No | No |
| 17028713 | A METHOD AND SYSTEM FOR INSULIN INFUSION RATE MANAGEMENT | September 2020 | June 2023 | Allow | 32 | 6 | 0 | No | No |
| 17013380 | METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY | September 2020 | February 2022 | Abandon | 17 | 2 | 0 | Yes | No |
| 16986042 | SYSTEM FOR DETERMINING A HEALTH STATUS OF A TISSUE OF INTEREST | August 2020 | June 2022 | Abandon | 22 | 4 | 1 | Yes | No |
| 16986057 | SYSTEM FOR DETERMINING A HEALTH STATUS OF A TISSUE OF INTEREST | August 2020 | October 2023 | Abandon | 39 | 6 | 1 | Yes | Yes |
| 16944048 | Method For Determining Genotypes in Regions of High Homology | July 2020 | August 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16934963 | Slope-Based Compensation | July 2020 | May 2023 | Abandon | 34 | 1 | 0 | No | No |
| 16930012 | SELF-DIRECTED METHOD FOR CELL-TYPE IDENTIFICATION AND SEPARATION OF GENE EXPRESSION MICROARRAYS | July 2020 | December 2023 | Abandon | 41 | 2 | 0 | No | No |
| 16889419 | Shear Force Generating Device for Analysis of Biopsied Mammalian Samples | June 2020 | October 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16875645 | METHODS AND SYSTEMS FOR DETECTING RESIDUAL DISEASE | May 2020 | October 2024 | Abandon | 53 | 4 | 1 | Yes | No |
| 16870703 | Biosensor Systems for Determining Analyte Concentration Based On Complex Index Functions | May 2020 | May 2024 | Abandon | 48 | 0 | 1 | No | No |
| 16860792 | A METHOD OF DETECTING AND TREATING ENDOMETRIOSIS IN A FEMALE SUBJECT | April 2020 | December 2021 | Allow | 20 | 2 | 1 | No | No |
| 16858463 | RESEARCH DATABASE | April 2020 | April 2024 | Abandon | 48 | 1 | 1 | No | No |
| 16691480 | METHOD OF TREATING CANCER | November 2019 | November 2020 | Allow | 12 | 2 | 1 | Yes | No |
| 16689727 | PROCESS, COMPUTER-ACCESSIBLE MEDIUM AND SYSTEM FOR GENERATING A BIOLOGICAL MODEL ASSOCIATED WITH DISEASE | November 2019 | January 2024 | Abandon | 50 | 1 | 0 | No | No |
| 16659544 | Hydration and Nutrition System | October 2019 | December 2023 | Abandon | 49 | 2 | 0 | No | No |
| 16656984 | GENE EXPRESSION PROFILES TO PREDICT BREAST CANCER OUTCOMES | October 2019 | March 2023 | Abandon | 41 | 1 | 0 | No | No |
| 16576643 | A METHOD FOR TREATING CANCER | September 2019 | August 2020 | Allow | 11 | 2 | 1 | No | No |
| 16574056 | A METHOD AND SYSTEM FOR ADMINISTERING A CORRECTION BOLUS TO A PATIENT | September 2019 | August 2022 | Abandon | 35 | 2 | 0 | Yes | Yes |
| 16561194 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR MAKING BASE CALLS IN NUCLEIC ACID SEQUENCING | September 2019 | December 2024 | Abandon | 60 | 2 | 1 | No | No |
| 16490084 | MONOMERIC BALANCE CONTROL IN THE PREPARATION OF PRECURSORS FOR POLYAMIDATION PROCESSES | August 2019 | August 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16452406 | METHODS AND SYSTEMS FOR SEQUENCING-BASED VARIANT DETECTION | June 2019 | January 2024 | Abandon | 54 | 1 | 1 | No | No |
| 16449272 | A METHOD OF OPERATING A MEASUREMENT SYSTEM TO ANALYZE A POLYMER | June 2019 | October 2023 | Allow | 52 | 6 | 1 | Yes | No |
| 16438757 | SYSTEMS AND METHODS FOR DETERMINING COPY NUMBER VARIATION | June 2019 | June 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16406715 | SEQUENCE VARIANT ANALYSIS OF CELL-FREE DNA FOR CANCER SCREENING | May 2019 | October 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16375237 | METHODS OF TREATING A SUBJECT WITH A HIGH GLEASON SCORE PROSTATE CANCER | April 2019 | February 2024 | Abandon | 59 | 2 | 0 | No | No |
| 16361741 | NUCLEIC ACID SEQUENCING APPARATUS FOR MONITORING STATUS OF A TRANSPLANT RECIPIENT | March 2019 | March 2021 | Allow | 23 | 3 | 0 | Yes | No |
| 16353590 | GENE EXPRESSION PROFILES TO PREDICT BREAST CANCER OUTCOMES | March 2019 | April 2022 | Abandon | 37 | 1 | 0 | No | No |
| 16273316 | METHOD AND APPARATUS FOR ESTIMATING TEMPERATURE IN A BODY | February 2019 | February 2023 | Allow | 48 | 2 | 0 | No | No |
| 16261037 | BIOMARKERS FOR TYPE 2 DIABETES MELLITUS AND USE THEREOF | January 2019 | December 2023 | Abandon | 59 | 2 | 1 | Yes | No |
| 16244459 | APPARATUS AND METHOD FOR TRANSCRIPTOME ANALYSIS | January 2019 | December 2023 | Abandon | 59 | 3 | 0 | No | No |
| 16208149 | A METHOD FOR ADMINISTERING A CANCER TREATMENT | December 2018 | May 2024 | Allow | 60 | 6 | 0 | Yes | No |
| 16188882 | DYNAMIC PERSONALIZED CANCER TREATMENT | November 2018 | October 2024 | Abandon | 60 | 4 | 0 | No | No |
| 16099975 | ORTHOGONAL APPROACH TO INTEGRATE INDEPENDENT OMIC DATA | November 2018 | March 2025 | Abandon | 60 | 3 | 1 | No | Yes |
| 16171596 | MACHINE LEARNING BASED ANTIBODY DESIGN | October 2018 | November 2022 | Abandon | 49 | 6 | 1 | Yes | No |
| 16093396 | USING THE FULL REPERTOIRE OF GENETIC INFORMATION FROM BACTERIAL GENOMES AND PLASMIDS FOR IMPROVED GENETIC RESISTANCE TESTS | October 2018 | February 2024 | Abandon | 60 | 2 | 1 | No | No |
| 16143708 | DETERMINATION OF JAK-STAT3 PATHWAY ACTIVITY USING UNIQUE COMBINATION OF TARGET GENES | September 2018 | June 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16136533 | SYSTEMS, METHODS, AND PROCESSOR-READABLE MEDIA FOR DETECTING DISEASE CAUSAL VARIANTS | September 2018 | September 2022 | Abandon | 48 | 0 | 1 | No | No |
| 16130886 | SYSTEMS AND METHODS FOR DE NOVO ASSEMBLY OF NUCLEOTIDE SEQUENCE READS USING A MODIFIED STRING GRAPH | September 2018 | September 2022 | Allow | 48 | 1 | 1 | No | No |
| 16126879 | Method, System and Computer Program Product for Evaluation of Insulin Sensitivity, Insulin/Carbohydrate Ratio, and Insulin Correction Factors in Diabetes from Self-Monitoring Data | September 2018 | October 2025 | Abandon | 60 | 6 | 0 | Yes | No |
| 16083492 | ALGORITHM AND AN IN VITRO METHOD BASED ON RNA EDITING TO SELECT PARTICULAR EFFECT INDUCED BY ACTIVE COMPOUNDS | September 2018 | December 2024 | Abandon | 60 | 4 | 1 | Yes | No |
| 16109508 | A SYSTEM FOR ADMINISTERING INSULIN BOLUSES TO A PATIENT | August 2018 | June 2020 | Allow | 22 | 3 | 0 | No | Yes |
| 16064107 | DETECTION OF CHROMOSOME ABNORMALITIES | June 2018 | April 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16006129 | A METHOD FOR ADMINISTERING A CHECKPOINT BLOCKADE THERAPY TO A SUBJECT | June 2018 | June 2020 | Allow | 24 | 2 | 1 | Yes | No |
| 15979374 | ADAPTIVE SIGNAL PROCESSING FOR INFUSION DEVICES AND RELATED METHODS AND SYSTEMS | May 2018 | October 2023 | Abandon | 60 | 1 | 1 | No | No |
| 15969603 | SYSTEM FOR DETERMINING A HEALTH STATUS OF A TISSUE OF INTEREST | May 2018 | March 2021 | Abandon | 34 | 5 | 0 | No | No |
| 15875197 | METHOD AND SYSTEM FOR DETERMINING INSULIN DOSING SCHEDULES AND CARBOHYDRATE-TO-INSULIN RATIOS IN DIABETIC PATIENTS | January 2018 | August 2022 | Abandon | 55 | 1 | 1 | No | No |
| 15862819 | METHOD AND SYSTEM FOR OPTIMIZING INSULIN DOSAGES FOR DIABETIC SUBJECTS | January 2018 | December 2020 | Abandon | 36 | 4 | 1 | No | Yes |
| 15820863 | SYSTEMS AND METHODS FOR TREATING, DIAGNOSING AND PREDICTING THE OCCURRENCE OF A MEDICAL CONDITION | November 2017 | March 2024 | Abandon | 60 | 5 | 0 | No | No |
| 15794915 | EVALUATING AND CALLING SEQUENCES | October 2017 | February 2022 | Abandon | 51 | 0 | 1 | No | No |
| 15561025 | NORMALIZATION METHODS FOR MEASURING GENE COPY NUMBER AND EXPRESSION | September 2017 | December 2021 | Abandon | 50 | 0 | 1 | No | No |
| 15707818 | METHOD AND SYSTEM FOR SELECTING DRUG ON BASIS OF INDIVIDUAL PROTEIN DAMAGE INFORMATION FOR PREVENTING SIDE EFFECTS OF DRUG | September 2017 | October 2021 | Abandon | 49 | 1 | 0 | No | No |
| 15686706 | SYSTEMS AND METHODS FOR TREATING, DIAGNOSING AND PREDICTING THE OCCURRENCE OF A MEDICAL CONDITION | August 2017 | October 2024 | Abandon | 60 | 6 | 0 | No | No |
| 15667236 | SYSTEMS AND METHODS FOR NUCLEIC ACID-BASED IDENTIFICATION | August 2017 | October 2025 | Abandon | 60 | 4 | 1 | No | Yes |
| 15667535 | A PATHWAY ANALYSIS COMPUTING SYSTEM AND METHOD | August 2017 | January 2021 | Allow | 42 | 4 | 1 | Yes | No |
| 15667534 | A METHOD FOR TREATING AN INDIVIDUAL PATIENT | August 2017 | September 2020 | Allow | 37 | 4 | 1 | Yes | No |
| 15667544 | A PATIENT-SPECIFIC CELLULAR PATHWAY ACTIVITY INFERENCE COMPUTER SYSTEM | August 2017 | November 2021 | Allow | 52 | 6 | 1 | Yes | No |
| 15666174 | PROTEOGENOMIC ANALYSIS SYSTEM AND METHODS | August 2017 | August 2021 | Abandon | 49 | 0 | 1 | No | No |
| 15538821 | SYSTEMS, METHODS, AND APPARATUSES FOR SEQUENCE ALIGNMENT | June 2017 | March 2024 | Abandon | 60 | 6 | 1 | No | No |
| 15616873 | Method And Computer System For Assessing Classification Annotations Assigned To DNA Sequences | June 2017 | July 2021 | Abandon | 52 | 1 | 1 | No | No |
| 15496419 | A METHOD AND CONTROLLER FOR ADMINISTERING RECOMMENDED INSULIN DOSAGES TO A PATIENT | April 2017 | March 2021 | Allow | 47 | 2 | 0 | No | No |
| 15487329 | METHOD AND SYSTEM OF ESTIMATING A SEQUENCE OF POLYMER UNITS | April 2017 | September 2024 | Allow | 60 | 10 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WHALEY, PABLO S.
With a 11.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WHALEY, PABLO S works in Art Unit 3619 and has examined 155 patent applications in our dataset. With an allowance rate of 38.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 59 months.
Examiner WHALEY, PABLO S's allowance rate of 38.1% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WHALEY, PABLO S receive 4.14 office actions before reaching final disposition. This places the examiner in the 98% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by WHALEY, PABLO S is 59 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +27.5% benefit to allowance rate for applications examined by WHALEY, PABLO S. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 8.0% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 15.6% of cases where such amendments are filed. This entry rate is in the 17% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 49% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 52.6% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 53.6% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 5.8% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 35% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.